Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04894838

DIStal gastriC Bypass OUtcome in Revision SurgEry After Roux-en-y Gastric Bypass

This study is designed as a prospective multicenter randomized controlled clinical trial comparing two surgical techniques of distal gastric bypass (DGB) in revisional surgery following failed Roux-en-Y gastric bypass. Patients will be randomly allocated 1:1 to A) DGB with lengthening of the BPL (DGB type I) or B) DGB with extended AL (DGB type II). Randomisation is stratified for participating center. The study will be performed in a clinical and out-patient setting with regular visits at 1.5, 3, 6, 12, 18, 24 and 36 months post intervention. The study will be set up as a multicenter study with bariatric centers: St. Antonius hospital, Groene Hart hospital, OLVG, Rijnstate hospital, Elisabeth Twee-steden Hospital, Bravis hospital, Medisch Centrum Leeuwarden, Catharina Hospital.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rijnstate Hospital, Arnhem, Gelderland, Netherlands

Loading trial locations.

About this study

Rationale: Up to 35% of morbidly obese patients undergoing Roux-en-Y gastric bypass (RYGB) fail to lose sufficient weight or regain excessive weight after initial weight loss. Currently, there is no standardized approach to revisional surgery after failed RYGB. Distalisation of the RYGB limbs (DGB), with shortening of the common channel and extending either the alimentary limb (AL) or biliopancreatic limb (BPL), can be performed as revisional surgery to induce additional weight loss. To date, there is no general consensus as to optimal surgical technique or limb lengths to be used in distalisation of RYGB in both literature as well as clinical practice.

Objective: The aim of this study is to investigate the effect of two distalisation techniques of a gastric bypass in revisional surgery with standardised limb lengths in total weight loss (TWL) and the need for treatment for protein calorie malnutrition (PCM). In this randomised controlled trial DGB with lengthening of the BPL (DGB type I) will be compared to DGB with extended AL (DGB type II) in order to conclude which surgical technique is the optimal therapeutic strategy as revision surgery following Roux-en-Y gastric bypass.

Study design: A multicentre randomised controlled trial.

Study population: Morbidly obese patients with insufficient weight loss or weight regain following primary RYGB, who are eligible for distalisation surgery.

Intervention: A total of 150 participants will be randomised over two treatment groups: group A will undergo DGB type I and group B will undergo DGB type II.

Main study endpoints: Primary endpoints: %TWL 1 year after treatment and need for treatment of PCM. Secondary endpoints: weight loss, co-morbidity remission, PCM grading (debilitating defecation patterns, temporary total parenteral nutrition treatment, revision, mortality), morbidity, nutritional deficiencies, quality of life and patient satisfaction.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-65 years;
  • BMI ≥40 kg/m2 or BMI ≥35 kg/m2 with obesity related comorbidity;
  • Weight regain or insufficient weight loss (EWL<50% or TWL<20%)15,16 following RYGB;
  • Multidisciplinary team screening at one of the bariatric centres;
  • Informed consent and willing to enter the follow-up program.

Exclusion criteria

  • Failed Roux-en-Y gastric bypass due to anatomic, surgical reasons (gastric pouch dilatation >50 mL, gastro-gastric fistula, gastro-jejunostomy);
  • Distalisation of RYGB is technical infeasible (judgment by surgeon);
  • Inflammatory bowel disease, celiac disease, irritable bowel syndrome and other causes of chronic diarrhea;
  • Severe concomitant disease (such as carcinomas and neurodegenerative disorders);
  • Pregnant women;
  • Noncompliance in follow-up or unwilling to undergo surgery;
  • Inability of reading/understanding and filling out questionnaires.

Treatment and study plan

Distal gastric bypass

Procedure

Distal gastric bypass, revisonal surgery after failed RYGB

Primary outcomes

  1. Weight loss

    Time frame: 1 year post-operative

    Percentage total weight loss (%TWL) 1 year after treatment

  2. Number of Participants with development of protein calorie malnutrition (PCM)

    Time frame: 1 year postoperative

    >6 times/day defecation patterns with diarrhea, assessed by fecal score questionnaire

Secondary outcomes

  1. Weight loss

    Time frame: Up to 3 year follow up

    Patient weight in kilograms is collected preoperative up to 3 years follow-up to determine weight loss.

  2. TWL

    Time frame: 3, 6, 12, 18, 24, 36 month follow up

    Weight loss in kilograms at a follow-up time point divided by weight in kilograms measured at DGB

  3. Defecation pattern

    Time frame: 3, 12 and 36 months postoperative

    Faecal score questionnaire to measure defecation frequencey and consistency

  4. PCM grading

    Time frame: up to 3 year follow up

    Information is collected about each patient who has undergone DGB to ascertain debilitating defecation patterns (grade I), requirement of f participants requiring temporary total parenteral nutrition (grade II, revision surgery (grade III), and mortality (grade IV) after DGB.

  5. Complications

    Time frame: uo to 3 year follow up

    Information is collecting regarding the occurrence of one or more defined adverse events following DGB. Defined adverse events collected are: unplanned readmission to hospital, unplanned admission to the intensive care unit, unplanned return to the operating theatre, prolonged length of stay in hospital, and death. The reason for any of the events is also collected. If death occurs, the cause of death is collected to determine the likelihood of the death being caused by the DGB.

  6. Quality of life questionnaire

    Time frame: 3, 12 and 36 months postoperative

    BODY-Q questionnaire

  7. Impact defecation pattern questionnaire

    Time frame: 3, 12 and 36 months postoperative

    Fecal incontinence quality of life scale FIQL questionnaires

  8. Patient satisfaction questionnaire

    Time frame: 1 and 3 year postoperative

    Self-designed 5-point scale measuring instrument for patient satisfaction

  9. Eating behaviour questionnaire

    Time frame: 3, 12 and 36 months postoperative

    Three factor earing questionnaire TFEQ R21

Study contacts

Contact information is provided by the study sponsor or research team.

Luna Tolenaars, MD

CONTACT

[email protected]

0031636434456

M.J. Wiezer, PhD, MD

CONTACT

[email protected]

0031 6418 73500

Sponsors and collaborators

Lead sponsor

St. Antonius Hospital

Other

Collaborators

  • Medtronic

Registry information

Acronym: DISCOURSE

Important dates

Study start
2021
Primary completion
2029
Study completion
2029
First posted
May 20, 2021
Registry last updated
Apr 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.